09:00 AM EDT, 08/18/2025 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Monday it has enrolled its first two patients in its pivotal phase 3 trial of eRapa in patients with familial adenomatous polyposis.

The trial patients were enrolled at the Pan American Center for Oncology Trials in San Juan, Puerto Rico, the company said.

The US component of the trial, incorporating 20 sites, is being managed by LumaBridge based in San Antonio, Texas, while the European component, consisting of 10 sites, will be conducted by Precision for Medicine, according to a statement.